Novo Nordisk Prepares For European NovoRapid Launch
Executive Summary
Novo Nordisk is likely to begin European marketing in late 1999 for NovoRapid (insulin aspart) in diabetes mellitus, following a recommendation for approval by the Committee for Proprietary Medicinal Products at its May 18-20 plenary session.
You may also be interested in...
Novo's NovoSeven Posts $19 Mil. In U.S. Sales Since April Launch
Novo Nordisk's hemophilia treatment NovoSeven (recombinant Factor VIIa) generated U.S. sales of approximately $19 mil. in its first three months on the U.S. market, Novo indicated in an Aug. 11 statement on half-year financial results. Novo began marketing the product in the U.S. in April.
Novo's NovoSeven Posts $19 Mil. In U.S. Sales Since April Launch
Novo Nordisk's hemophilia treatment NovoSeven (recombinant Factor VIIa) generated U.S. sales of approximately $19 mil. in its first three months on the U.S. market, Novo indicated in an Aug. 11 statement on half-year financial results. Novo began marketing the product in the U.S. in April.
Novo's NovoRapid Has 10-20 Min. Onset Of Action - EU Labeling
Novo Nordisk's diabetes mellitus treatment insulin aspart has an onset of action time of 10 to 20 minutes, according to European draft labeling for the human insulin analogue.